In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:
- Key Comorbidities in Patients with HR+/HER2- MBC
- Impact of Polypharmacy
- Role of APPs in Comprehensive Care
- Role of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBC
- Utility of RWE data
- Communicating Treatment Options With Patients and Caregivers
- Understanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of Life
Link to full program:
https://bit.ly/4jCQe38
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Decera Clinical Education Oncology Podcast